Ark Genomic Revolution Etf Fundamentals

ARKG Etf  USD 23.22  0.14  0.60%   
ARK Genomic Revolution fundamentals help investors to digest information that contributes to ARK Genomic's financial success or failures. It also enables traders to predict the movement of ARK Etf. The fundamental analysis module provides a way to measure ARK Genomic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ARK Genomic etf.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ARK Genomic Revolution ETF Price To Earning Analysis

ARK Genomic's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

 = 

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Current ARK Genomic Price To Earning

    
  41.86 X  
Most of ARK Genomic's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ARK Genomic Revolution is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition

Based on the latest financial disclosure, ARK Genomic Revolution has a Price To Earning of 41.86 times. This is much higher than that of the ARK ETF Trust family and significantly higher than that of the Health category. The price to earning for all United States etfs is notably lower than that of the firm.

ARK Genomic Revolution Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining ARK Genomic's current stock value. Our valuation model uses many indicators to compare ARK Genomic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ARK Genomic competition to find correlations between indicators driving ARK Genomic's intrinsic value. More Info.
ARK Genomic Revolution is the top ETF in price to earning as compared to similar ETFs. It is second largest ETF in price to book as compared to similar ETFs fabricating about  0.08  of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for ARK Genomic Revolution is roughly  12.84 . Comparative valuation analysis is a catch-all technique that is used if you cannot value ARK Genomic by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Did you try this?

Run Share Portfolio Now

   

Share Portfolio

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Fund Asset Allocation for ARK Genomic

The fund invests 99.63% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.
Asset allocation divides ARK Genomic's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.

ARK Fundamentals

About ARK Genomic Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ARK Genomic Revolution's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARK Genomic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARK Genomic Revolution based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
The fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the funds investment theme of the genomics revolution . Ark Genomic is traded on BATS Exchange in the United States.

Currently Active Assets on Macroaxis

When determining whether ARK Genomic Revolution is a strong investment it is important to analyze ARK Genomic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ARK Genomic's future performance. For an informed investment choice regarding ARK Etf, refer to the following important reports:
Check out ARK Genomic Piotroski F Score and ARK Genomic Altman Z Score analysis.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.